title: [Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia].
abstract: We assessed effect of 6-weeks therapy with atorvastatin on parameters of lipid metabolism and some hemorheological characteristics in 27 patients with arterial hypertension (AH) and dyslipoproteinemia (DLP). In addition to general clinical examination we studied hemorheological profile including hematocrit, blood plasma and whole blood viscosity with the method of rotational viscosimetry at various shear rates, deformability of erythrocytes by filtration method, and cytoarchitectonics of erythrocytes. At the background of pronounced lipid lowering effect of atorvastatin we noted obvious improvement of microrheological properties of erythrocytes appearing as significant decrease of rigidity index of erythrocytes and of their aggregation. Basing on these findings we concluded that improvement of fluidity of erythrocytes promoting facilitation of blood flow efficacy in microcirculatory vascular bed can be a supplementary reason for administration of atorvastatin to patients with AH and DLP.
authors.forename: E D
authors.initials: ED
authors.lastname: Abrashkina
authors.forename: N
authors.initials: N
authors.lastname: Shaalali
authors.forename: O A
authors.initials: OA
authors.lastname: Pakhrova
authors.forename: E A
authors.initials: EA
authors.lastname: Shutemova
authors.forename: O A
authors.initials: OA
authors.lastname: Nazarova
mesh_terms: D000328:Adult; D017311:Amlodipine / Q000008:administration & dosage / Q000627:therapeutic use*; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069059:Atorvastatin; D001809:Blood Viscosity; D003627:Data Interpretation, Statistical; D050171:Dyslipidemias / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D004903:Erythrocyte Aggregation; D004907:Erythrocyte Deformability; D005260:Female; D006400:Hematocrit; D018056:Hemorheology; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006973:Hypertension / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D017311:Amlodipine; D000069059:Atorvastatin